Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2020-01-31 Declaration of Voting R…
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Increase of number of shares and votes in Vicore Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces an 'Increase of number of shares and votes in Vicore Pharma' due to the exercising of warrants. This directly relates to a change in the company's capital structure (issuance of new shares). This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). The document is a formal announcement detailing the change in outstanding shares and registered share capital.
2020-01-31 English
Ökning av antalet aktier och röster i Vicore Pharma
Share Issue/Capital Change Classification · 98% confidence The document is a short announcement from Vicore Pharma dated November 29, 2019, detailing an increase in the number of outstanding shares and votes following a directed new share issue (nyemission) of 7,800,000 shares. This action directly relates to changes in the company's capital structure and share count. This fits the definition of 'Capital/Financing Update' (CAP), as it announces the result of a fundraising/capital structure change. It is not a full report (10-K, IR), a dividend notice (DIV), or a general regulatory filing (RNS), but a specific announcement about capital changes.
2019-11-29 Swedish
Increase of number of shares and votes in Vicore Pharma
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces an 'Increase of number of shares and votes' following a directed share issue, detailing the number of new shares issued (7,800,000), the subscription price (SEK 16), the resulting total outstanding shares (50,174,714), and the new registered share capital. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not an earnings release, an annual report, or a simple announcement of a report publication.
2019-11-29 English
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for 'Fjärde AP-fonden' in 'Vicore Pharma Holding AB'. It explicitly states the 'Reason for major shareholding notification' and provides 'Before the transaction' and 'After the transaction' figures, including the resulting percentage of voting rights (6.4%). This content directly corresponds to the definition of a Major Shareholding Notification, which is classified as 'MRQ'. The document is a formal notification of ownership change, not a general regulatory filing (RNS) or an announcement of a report (RPA).
2019-11-14 English
Vicore Pharma har genomfört en riktad nyemission om cirka 125 miljoner kronor
Capital/Financing Update Classification · 99% confidence The document is a press release dated November 13, 2019, announcing that Vicore Pharma has successfully completed a directed new share issue ('riktad nyemission') raising approximately 125 million SEK. The text details the number of shares issued, the subscription price, the use of proceeds (financing drug development programs VP01 and VP02), and the resulting dilution and capital increase. This activity directly relates to the company raising capital and changing its capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it describes a specific corporate financing event.
2019-11-13 Swedish
Vicore Pharma has completed a directed share issue of approximately SEK 125 million
Share Issue/Capital Change Classification · 98% confidence The document is a press release announcing the successful completion of a 'directed share issue of approximately SEK 125 million'. It details the number of shares issued, the subscription price, the use of proceeds (financing drug development), and mentions lock-up agreements. This activity directly relates to raising capital and changing the company's capital structure through the issuance of new shares. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Earnings Release (ER), Interim Report (IR), or a formal regulatory filing like a 10-K, but rather a specific corporate finance announcement.
2019-11-13 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.